Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha-1-antitrypsin Deficiency
Conditions
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Trial Timeline
Jan 1, 2012 → Feb 1, 2017
NCT ID
NCT01379469About Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) Placebo
Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) Placebo is a phase 2 stage product being developed by Novartis for Alpha-1-antitrypsin Deficiency. The current trial status is terminated. This product is registered under clinical trial identifier NCT01379469. Target conditions include Alpha-1-antitrypsin Deficiency, Liver Cirrhosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01379469 | Phase 2 | Terminated |